Patrick Ryan Potts

Patrick Ryan Potts

Auto-generated profile, based on publicly available information

Patrick Ryan Potts

Induced Proximity Platform, Amgen Research, Thousand Oaks, CA 91320, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Molecular Cell
Verified
Journal Article
Closed access
JDJennifer M. Doyle
Jennifer M. Doyle
JGJinlan Gao
Jinlan Gao
JWJiawei Wang
Jiawei Wang
MYMaojun Yang
Maojun Yang
PPPatrick Ryan Potts
Patrick Ryan Potts

1 February 2015 in Cell
Verified
Journal Article
Closed access
CPCarlos T. Pineda
Carlos T. Pineda
SRSaumya Ramanathan
Saumya Ramanathan
KTKlementina Fon Tacer
Klementina Fon Tacer
JWJenny L. Weon
Jenny L. Weon
MPMalia B. Potts
Malia B. Potts
PPPatrick Ryan Potts
Patrick Ryan Potts

19 May 2022 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
RGRobert G. Guenette
Robert G. Guenette
SYSeung Wook Yang
Seung Wook Yang
JMJaeki Min
Jaeki Min
BPBaikang Pei
Baikang Pei
PPPatrick Ryan Potts
Patrick Ryan Potts
Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle challenging protein targets deemed undruggable with traditional small molecule inhibitors. Many promising campaigns to inhibit proteins have failed due to factors surrounding inhibition selectivity and targeting of compounds to specific tissues and cell types. One of the major improvements that PROTAC (proteolysis targeting chimera) and molecular glue technology can exert is highly selective control of target inhibition. Multiple studies have shown that PROTACs can gain selectivity for their protein targets beyond that of their parent ligands via optimization of linker length and stabilization of ternary complexes. Due to the bifunctional nature of PROTACs, the tissue selective nature of E3 ligases can be exploited to uncover novel targeting mechanisms. In this review, we provide critical analysis of the recent progress towards making selective PROTAC molecules and new PROTAC technologies that will continue to push the boundaries of achieving selectivity. These efforts have wide implications in the future of treating disease as they will broaden the possible targets that can be addressed by small molecules, like undruggable proteins or broadly active targets that would benefit from degradation in specific tissue types.

1 December 2015 in Current Opinion in Cell Biology
Verified
Journal Article
Closed access
JWJenny L Weon
Jenny L Weon
PPPatrick Ryan Potts
Patrick Ryan Potts

1 February 2013 in Cell
Verified
Journal Article
Closed access
YHYi-Heng Hao
Yi-Heng Hao
JDJennifer M. Doyle
Jennifer M. Doyle
SRSaumya Ramanathan
Saumya Ramanathan
TGTimothy S. Gomez
Timothy S. Gomez
Da JiaDa Jia
Da Jia
PPPatrick Ryan Potts
Patrick Ryan Potts

1 August 2005 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
PPPatrick Ryan Potts
Patrick Ryan Potts
HYHongtao Yu
Hongtao Yu
DNA repair is required for the genomic stability and well-being of an organism. In yeasts, a multisubunit complex consisting of SMC5, SMC6, MMS21/NSE2, and other non-SMC proteins is required for DNA repair through homologous recombination. The yeast MMS21 protein is a SUMO ligase. Here we show that the human homolog of MMS21 is also a SUMO ligase. hMMS21 stimulates sumoylation of hSMC6 and the DNA repair protein TRAX. Depletion of hMMS21 by RNA interference (RNAi) sensitizes HeLa cells toward DNA damage-induced apoptosis. Ectopic expression of wild-type hMMS21, but not its ligase-inactive mutant, rescues this hypersensitivity of hMMS21-RNAi cells. ATM/ATR are hyperactivated in hMMS21-RNAi cells upon DNA damage. Consistently, hMMS21-RNAi cells show an increased number of phospho-CHK2 foci. Finally, we show that hMMS21-RNAi cells show a decreased capacity to repair DNA lesions as measured by the comet assay. Our findings suggest that the human SMC5/6 complex and the SUMO ligase activity of hMMS21 are required for the prevention of DNA damage-induced apoptosis by facilitating DNA repair in human cells.